Impact of age on functional exercise correlates in patients with advanced lung cancer

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1277-1283

  Wang, Li Ying ^a,b   Wu, Huey Dong ^b   Chen, Kuan Yu ^b   Hsieh, Chen Hsi ^c,d   Lai, Chung Chun ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

6 minute walk test; Advanced lung cancer; Age; Respiratory muscle strength; Spirometry

Indexed keywords

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CONTROLLED STUDY; DYSPNEA; EXERCISE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL STATUS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMAL EXPIRATORY PRESSURE; MAXIMAL INSPIRATORY PRESSURE; PROSPECTIVE STUDY; WEIGHT REDUCTION;

EID: 84884274042     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S50869     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-117.
3. Guyatt GH, Townsend M, Keller J, Singer J, Nogradi S. Measuring functional status in chronic lung disease: conclusions from a randomized control trial. Respir Med. 1989;83(4):293-297.
4. Kasymjanova G, Correa JA, Kreisman H, et al. Prognostic value of the six-minute walk in advanced non-small cell lung cancer. J Thorac Oncol. 2009;4(5):602-607.
5. Saqlam M, Arikan H, Savci S, et al. Relationship between respiratory muscle strength, functional capacity and quality of life in pre-operative cardiac surgery patients. Eur Respir Rev. 2008;17(107):39-40.
6. Camarri B, Eastwood PR, Cecins NM, Thompson PJ, Jenkins S. Six minute walk distance in healthy subjects aged 55-75 years. Respir Med. 2006;100(4):658-665.
7. Dudgeon DJ, Lertzman M. Dyspnea in the advanced cancer patient. J Pain Symptom Manage. 1998;16(4):212-219.
8. Dudgeon DJ, Lertzman M, Askew GR. Physiological changes and clinical correlations of dyspnea in cancer outpatients. J Pain Symptom Manage. 2001;21(5):373-379.
9. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations)[webpage on the Internet]. Bethesda, MD: National Cancer Institute; 2011. [updated April 2012]. Available from: http://seer.cancer.gov/csr/1975_2009_pops09/.
10. Sessums LL, Zembrzuska H, Jackson JL. Does this patient have medical decision-making capacity? JAMA. 2011;306(4):420-427.
11. American Thoracic Society/European Respiratory Society. ATS/ERS statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002;166(4):518-624.
12. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med. 1995;152(3):1107-1136.
13. Ip MS, Ko FW, Lau AC, et al; Hong Kong Thoracic Society; American College of Chest Physicians (Hong Kong and Macau Chapter). Updated spirometric reference values for adult Chinese in Hong Kong and implications on clinical utilization. Chest. 2006;129(2): 384-392.
14. Mahoney FI, Barthel D. Functional evaluation: the Barthel index. Md State Med J. 1965;14:61-65.
15. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer. 1948;1(4): 634-656.
16. Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J. 1999;14(2):270-274.
17. Mahler DA, Rosiello RA, Harver A, Lentine T, McGovern JF, Daubenspeck JA. Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease. Am Rev Respir Dis. 1987;135(6):1229-1233.
18. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5): 489-495.
19. Bowerman BL, O'Connell RT. Linear Statistical Models: An Applied Approach. 2nd ed. Belmont, CA: Duxbury; 1990.
20. Noseda A, Carpiaux JP, Prigogine T, Schmerber J. Lung function, maximum and submaximum exercise testing in COPD patients: reproducibility over a long interval. Lung. 1989;167(4):247-257.
21. Guyatt GH, Thompson PJ, Berman LB, et al. How should we measure function in patients with chronic heart and lung disease? J Chronic Dis. 1985;38(6):517-524.
22. Holden DA, Rice TW, Stelmach K, Meeker DP. Exercise testing, 6-min walk, and stair climb in the evaluation of patients at high risk for pulmonary resection. Chest. 1992;102(6):1774-1779.
23. Pierce RJ, Copland JM, Sharpe K, Barter CE. Preoperative risk evaluation for lung cancer resection: predicted postoperative product as a predictor of surgical mortality. Am J Respir Care Med. 1994;150(4):947-955.
24. Jones LW, Hornsby WE, Goetzinger A, et al. Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. Lung Cancer. 2012;76(2):248-252.
25. Miller KL, Kocak Z, Kahn D, et al. Preliminary report of the 6-minute walk test as a predictor of radiation-induced pulmonary toxicity. Int J Radiat Oncol Biol Phys. 2005;62(4):1009-1013.
26. Bryant AS, Cerfolio RJ. Differences in outcomes between younger and older patients with non-small cell lung cancer. Ann Thorac Surg. 2008;85(5):1735-1739.
27. Pemberton JH, Nagorney DM, Gilmore JC, Taylor WF, Bernatz PE. Bronchogenic carcinoma in patients younger than 40 years. Ann Thorac Surg. 1983;36(5):509-515.
28. Nugent WC, Edney MT, Hammerness PG, Dain BJ, Maurer LH, Rigas JR. Non-small cell lung cancer at the extremes of age: impact on diagnosis and treatment. Ann Thorac Surg. 1997;63(1):193-197.
29. Casanova C, Celli BR, Barria P, et al; Six Minute Walk Distance Project (ALAT). The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J. 2011;37(1):150-156.
30. Cheville AL, Novotny PJ, Sloan JA, et al. The value of a symptom cluster of fatigue, dyspnea, and cough in predicting clinical outcomes in lung cancer survivors. J Pain Symptom Manage. 2011;42(2):213-221.
31. Bredin M, Corner J, Krishnasamy M, Plant H, Bailey C, A'Hern R. Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer. BMJ. 1999;318(7188): 901-904.
32. Koelwyn GJ, Jones LW, Hornsby W, Eves ND. Exercise therapy in the management of dyspnea in patients with cancer. Curr Opin Support Palliat Care. 2012;6(2):129-137.
33. Travers J, Dudgeon DJ, Amjadi K, et al. Mechanisms of exertional dyspnea in patients with cancer. J Appl Physiol. 2008;104(1):57-66.
34. Dudgeon DJ, Kristjanson L, Sloan JA, Lertzman M, Clement K. Dyspnea in cancer patients: prevalence and associated factors. J Pain Symptom Manage. 2001;21(2):95-102.
35. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P; International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM Classification of Malignant Tumors and the proposals for the 7th edition. J Thorac Oncol. 2008;3(5):457-466.
36. Novoa NM, Varela G, Jiménez MF, Ramos J. Value of the average basal daily walked distance measured using a pedometer to predict maximum oxygen consumption per minute in patients undergoing lung resection. Eur J Cardiothorac Surg. 2011;39(5):756-762.
37. Yang R, Cheung MC, Pedroso FE, Byrne MM, Koniaris LG, Zimmers TA. Obesity and weight loss at presentation of lung cancer are associated with opposite effects on survival. J Surg Res. 2011;170(1):e75-e83.
38. Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency in the United States. JAMA. 1997;277(12): 973-976.
39. Opden Kamp CM, Langen RC, Minnaard R, et al. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer. 2012;76(1):112-117.